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Abstract Drypowder inhalers are designedwithresistance to air£ow so that a respirable cloud of particles is gener-
ated during inhalation. Some of these devices require a certain inhalation rate to produce a consistentdose of respirable
particles.The aimof the study was to determine the inhalation rate of elderlypatientswith chronic obstructive pulmon-
arydisease (COPD)whentheyinhale through aTurbuhalersandassess thepotentialofthe In-CheckMeters to identify
inhalation rates.Their peak inhalation rate using a normal inhalation, pre- and post-counselling, was measured using a
TurbuhalerTrainersandan In-CheckMeters.Spirometrywasalsomeasured.Seventy-fourCOPDpatientswithamean
(SD) age of 79?7 (8?4) years and forced expiratory volume in 1 sec (FEV1) 41?9 (12?8)% predicted. Pre-counselling 14
obtained a rate of o30 lminÿ1with theTurbuhalerTrainer, 31 from 30 to 40 minÿ1, 23 between 40^60 lminÿ1 and 6
460 lminÿ1. The median (range) peak inhalation rates with the In-Check Meters were 50 (50^70), 70 (50^130),100
(60^200) and 225 (200^250) lminÿ1.Post-counselling 7,16,41and10 achieved the respective peak inhalation rates using
theTurbuhalerTrainers Similarly, the In-Checkinhalationrateswere 50 (50^60),70 (50^130),90 (60^200) and 250 (200^
270) lminÿ1.The results highlightthe potential of the In-Check Meters to identify patients’ inhalation rates through dry
powder inhalers.r2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1190, available online at http://www.idealibrary.comon
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Dry powder inhalers (DPIs) are more expensive than a
metered-dose inhaler (MDI) but their use is increasing
because they are easier to use, are breath-actuated,
environmentally friendly and most have a dose counter.
Internally, they are designed so that a patient’s inhalation
rateproduces su⁄cient force to generate a cloud of drug
particles capable of delivery into the airways.This force
is generated by resistance in the device. It has been
shown that each type of inhaler device has a di¡erent re-
sistance (1,2).
In-vitro studies have shown that dose emission from a
Turbuhalers for budesonide (3) and terbutaline (3,4) is
related to the inhalation rate and subsequently with
total lung deposition (5,6) and response to terbutaline
(6,7) andbudesonide (8). Studies using other deviceswithReceived 7 Febuary 2001and accepted in revised form 6 August 2001.
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lated to inhalation rate (9^11) and response (11). How-
ever, it is di⁄cult to compare bronchodilation between
doses, devices and inhalation methods because of maxi-
mal response obtained duringmost single studies. New-
man et al. (12) highlighted this issue using asthmatic
subjects. They reported that although lung deposition,
measured by gamma scintigraphy, was 12?3% for a MDI
and 23?5%when theMDIwas attached to a spacer there
was no di¡erence in the forced expiratory volume in 1
sec (FEV1) response.
Studies in asthmatics (13,14) and chronic obstructive
pulmonary disease (COPD) (15) have shown that over
half of the patients studied cannot use theTurbuhalers
with the recommended most desirable rate of 460
lminÿ1 (5,16). In these studies (13^15) spirometry values
were not able to identify which patients could use this
device with the desirable rate.The relationship between
inspiratory and expiratory air£ow is not strong enough
to predictwhether patients are able to generate an inha-
lation rate for optimal drug delivery from an inhaler to
the airways (17,18). Hirsch et al. (19) have shown how
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a Turbuhalers. The product information lea£et explains
that the inhalation techniqueused should include an inha-
lation that is ‘as deep and hard as possible’. However pa-
tients with a reduced inspiratory capacity may not
generate the necessary inhalation rate that is required
for consistent and reliable dose emission. In the past
measurements of inhalation rates through an inhaled de-
vice have required sophisticated equipment.Recently an
In-Check Meters (Clement Clarke Ltd, Harlow, U.K.)
has been introduced to determine inhalation rates. This
device is similar in design and appearance to a peak
expiratory £ow meter except that an inhalation is
performed instead of a forced exhalation.Using a normal
inhalation technique this In-Check Meters is a simple
and quick method to measure the inhalation rate of
patients. In this study we have evaluated the potential of
this meter to identify how patients use a Turbuhalers,
with and without counselling, according to the manu-
facturer’s patient information lea£et.
METHODS
Local Ethics Research Committee approval was ob-
tained and patients gave informed, written consent. All
were elderly with chronic obstructive pulmonary dis-
ease (COPD), either inpatients or outpatients attending
their ¢rst appointment post-discharge. At the time of
measurement all in-patients had been stabilized and
were ready for discharge. Also spirometry measure-
mentswere similar to thosemeasured over the previous
6 months. Subjects inhaled through a Turbuhaler
Trainers (Astra Draco, Lund, Sweden) using their nor-
mal inhalation technique.They were given the patient in-
formation lea£et and allowed to study the instructions
for 5 min.TheTurbuhalerTrainers categorizes the peak
inhalation rate (PIFR-T) aso30, 30^40,40^60 and460
lminÿ1according to none, one, two or threegreen lights.
In-vitro measurements (n = 22) identi¢ed that the meanTABLE 1 Median (range) inspiratory and expiratorydata
PIFR-T n PIFR-IC (lminÿ
(a) Pre-counselling
o30 14 50 (50^70)
30^40 31 70 (50^130)
40^60 23 100 (60^200
460 6 225 (200^225
(b) Post-counselling
o30 7 50 (50^60)
30^40 16 70 (50^130)
40^60 41 90 (60^200)
460 10 250 (200^270(SD) rate to illuminate one, two and three lights of the
Turbuhaler Trainers was 28?8 (1?1), 39?6 (2?2) and 60?6
(1?9) lminÿ1.Patients thenused the same inhalation tech-
nique using the In-Check Meters (PIFR-IC) (Clement
Clarke) and their peak inhalation rate was recorded.
They were then counselled how to use theTurbuhalers
according to the manufacturer’s instructions in the pa-
tient information lea£et with particular attention drawn
to inhale through theirmouth as ‘deeply andhard as they
could’.Measurements with theTurbuhalers (PIFR-T) and
In-Check Meters (PIFR-IC) were then repeated. Finally,
spirometry (best of three forced expirations) was mea-
sured.
RESULTS
Seventy-four (44 females) with a mean (SD) age of 79?7
(8?4) years, FEV1 41?9 (12?8)% predicted and PEFR 50?4
(17)% predicted completed the study. Their mean (SD)
FEV1 and PEFR was 0?51 (0?36) and 177 (70) l min
ÿ1,
respectively. Ten were outpatients, the remainder were
inpatients ready for discharge. Fifty-one patients used
an MDI (13 with a spacer),16 aTurbuhalers, six a breath-
activated MDI and one had an Accuhalers. Table 1 pro-
vides a summary of inspiratory and expiratory £ow data
pre- and post-counselling. Table 1 shows that only six of
the 74 patients could inhale through theTurbuhalers at
a rate of 460 lminÿ1 and that counselling enabled an-
other four to achieve the optimal inhalation rate of
460 lminÿ1 through this device.Only two of the 16 pa-
tientswho used aTurbuhalers could achieve this optimal
rate. Statistical analysis (Kruskal^Wallis) showed signi¢-
cant di¡erences (Po0?001) for PIFR-IC, PEFR and FEV1
for each PIFR-T category.However, Fig.1and Table1high-
light that only those patients who could inhale at a rate
of4200 lminÿ1through the In-CheckMeters (PIFR-IC)
could use the Turbuhalers (PIFR-T) with an inhalation
rate460 lminÿ1. The mean (SD) PIFR-IC for the PIFR-T
categories ofo30, 30^40,40^60 and460 lminÿ1 prior1) PEFR(lminÿ1) FEV1 (l)
110 (60^150) 0?67 (0?33^1?15)
150 (110^200) 0?76 (0?51^1?51)
) 200 (100^350) 1?03 (0?56^2?00)
) 240 (230^350) 0?37 (1?10^1?48)
100 (60^150) 0?51 (0?33^0?98)
150 (60^360) 0?79 (0?41^1?25)
180 (110^350) 0?78 (0?51^2?00)
) 290 (100^350) 1?31 (0?82^1?70)
FIG. 1. Therange of peakinhalationrates obtainedwiththe In-
Check Metersbefore (&) and after (&) counselling for thein-
halationratesmeasuredusing aTurbuhalerTrainers (n = 74).
USINGTHEIN-CHECKMETERTOIDENTIFYINHALATIONRATES 967to counselling were 53?6 (6?3), 73?9 (19?3),117?3 (47?6) and
226?7 (20?7) lminÿ1, respectively. After counselling the
respective PIFR-IC rates were 51?4 (3?8), 73?1 (70?7),
102?6 (37?2) and 232?0 (22?0). Statistical analysis (Mann^
Whitney) showed no di¡erence for PIFR-IC, FEV1 or
PEFR before and after counselling for each PIFR-T cate-
gory.Correlations between either PIFR-Tor PIFR-ICwith
spirometry wereweak.
DISCUSSION
There is evidence that there is a link between the ¢ne
particlemass emitted from an inhaler with total lung de-
position (20). However, this may not be shown by mea-
surements of clinical e¡ect due to maximal response
(12). For dry powder inhalers that emit a £ow dependent
respirable dose, there is evidence of a reduced clinical ef-
fect at low inhalation £ow rates when using these inha-
lers (6,8,11,19). For some inhalers there is an optimal, i.e.
desirable / most favourable rate for inhalation (6,16). It is
important to identify the patients who can use each in-
dividual device. The In-Check Meters is a simple and
easy to use measurement which identi¢es inhalation
rates and thus is a useful aid.
Peak inhalation rates rather than a peak inspiratory
rate from a forced manoeuvre were measured during
this study to mimic how patients use inhalers. Dewar et
al. (15) reported that 41% of their COPD patients could
inhale at the optimal rate through aTurbuhalers. Their
patients were younger although the PEFRwas similar to
that of this study. Also, Dewer et al. (15) used theTurbu-
halers attached to a vitalograph in reverse mode and
counselled their patients to make forced inhalations.
Clark and Hollingworth (1) have highlighted that during
these measurements the technique to be used with
each inhaler should be assessed not a forcedmanoeuvre.
A short sharp suck will provide a greater inspirationthan that during more prolonged inhalation through an
inhaler.
A value of460 lminÿ1 has been quoted as the most
favourable inhalation rate when using a Turbuhaler
(5,6,16,18). The National Institute of Clinical Excellence
(NICE) has produced a report that identi¢es the high re-
sistance of theTurbuhalers and that it ‘needs a relatively
high inspiratory £ow of 60 lminÿ1 for optimal drug deliv-
ery’(21). The measurements with the Turbuhalers indi-
cate that most elderly COPD patients may not obtain
the nominal dosebecause they cannotgenerate theopti-
mal inhalation rate of460 lminÿ1. Pre-counselling14 pa-
tients and post-counselling seven could not generate
430 lminÿ1. Although the patients inhaling between
30^60 lminÿ1 through the Turbuhalers do not obtain
the nominal dose their condition can be managed by ti-
tration according to response.However, this couldbedif-
¢cult to perceive for those that are irreversible and
cannotbe applied to the anti-in£ammatory agents.Using
unnecessary extra reliever doses complicates manage-
ment plans and increases themedication costs. Further-
more when patients deteriorate their inspiratory e¡ort
will decrease (22) and thus they will obtain a reduced
dose which may aggravate the deterioration.These, pa-
tients with insu⁄cient inspiratory e¡ort should, there-
fore, be prescribed an inhaler with less resistance. The
In-Check measurements highlight how these patients
can easily be identi¢ed.
The results indicate how counselling can improve the
inhalation techniquebut the changeswere only small and
thuswhen the healthcare costs are considered itwill not
be cost e¡ective. Studies have questioned thevalue of in-
halation technique trainingbecausemanypatients revert
to their poor inhaler technique when they get home
(23^25).When a patient uses an inhaler the inspiratory
£ow generated is dependent on the capacity of their re-
spiratory muscle and the resistance within their airways
(26,27).The pre-counselling values were therefore close
to themaximum they could achieve and suggest that this
group of patients would not bene¢t from counselling
about their technique. The patient’s unable to achieve
the most favourable inhalation rate when they inhaled
‘as deep and hard as you can’ will not be able to achieve
the full bene¢t when they use aTurbuhalers.Other dry
powder inhalers also have a most desirable inhalation
rate. Thus, if the Turbuhaler Trainers was used alone
then blindly prescribing another inhaler is not the ideal
solution. The In-Check Meters used in this study was
the ¢rst version introduced and thus all inhalation rates
were measured with no resistance to air£ow.The study
highlights how this simplemeter canbeused to identify a
patient’s natural (untrained) inspiratory e¡ort. Recently,
a new version, the In-Check Dial, has been introduced
which can mimic the resistance of a selection of inhaled
products.The accuracy of this new version to identify in-
halation rates, when set for di¡erent inhalers, has been
968 RESPIRATORYMEDICINEreported (28).Using a single meter rather than one for
each inhaler provided by themanufacturer will be easier
to use in the clinic. The inhalation rate of uncounselled
patients through di¡erent inhalers can nowbemeasured
using the In-Check Dial.From the results obtainedusing
this device the most suitable inhaler, without technique
training, for each individual can be identi¢ed. The ideal
device would be one were the inhalation rate obtained
is towards the middle of the most desirable range for
that inhaler to account for the natural intra-individual
variability of inhalation rates (28).We now have studies
in progress to evaluate the potential of the In-Check
Dial in the clinic as an aid to prescribing.
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